NCT05103904 2026-04-21Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver TransplantEmory UniversityPhase 2 Terminated3 enrolled
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT03867370 2023-11-29Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular CarcinomaShanghai Junshi Bioscience Co., Ltd.Phase 1/2 Terminated40 enrolled
NCT04428437 2023-10-05Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint InhibitorsHumanity & Health Medical Group LimitedTerminated17 enrolled
NCT03433703 2019-12-06Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)Eisai Inc.Phase 2 Terminated8 enrolled 8 charts